Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GCL vs WOK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GCL Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–1 Matrix Metrics)

GCL Overall Winner 6-Pillar Tally: GCL 3 – 1 WOK (2 Tie) Matrix Metrics: GCL 7 – 1 WOK

As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin).

  • Defensive Composite Rating Caution: Although GCL compares more favorably head-to-head, both GCL (31.6/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GCL vs WOK
GCL NASDAQ Head-to-Head Winner
GCL Global Holdings Ltd Ordinary Shares
Services-Prepackaged Software
$1.16
-2.93% 1D
Market Cap $153.0M
TTM Revenue $239M
Forward P/E N/M
Beta / 30D Vol 1.52β · 75% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 50.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (22.9% over 20 days), RSI 71
RSI-14: 70.6 · SMA20: $0.98 · SMA50: $0.82
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.23
+2.5% 1D
Market Cap $5.4M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 38.49β · 153% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 5.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $1.13 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (GCL 3 – 1 WOK)

Columns: Metric · GCL · WOK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.6x 0.5x
2. Growth & Scale GCL
Revenue Growth (YoY) +53.8% +19.1%
Earnings Growth (YoY) N/A -95.0%
TTM Revenue (USD) $239M $11M
Market Cap $153.0M $5.4M
3. Profitability & Quality GCL
Gross Margin 10.3% 17.0%
Operating Margin -5.5% -41.7%
Net Profit Margin -10.5% -41.9%
Return on Equity (ROE) -67.3% -19.2%
4. Balance Sheet & Cash Flow GCL
Cash Generation (TTM) -$12M EBITDA -$3.4M EBITDA
Cash Flow Margin -4.9% EBITDA Mgn -31.4% EBITDA Mgn
Net Cash / Leverage $0.29 Book/Sh · -67.3% ROE $1855.16 Book/Sh · -19.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat WOK
OpEx & R&D Intensity 15.8% of Rev ($38M) 58.7% of Rev ($6.3M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Electronic Gaming & Multimedia Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GCL (7) vs WOK (1)
Institutional Metric GCL WOK Criterion Row Edge
Market Capitalization
Scale
$153.0M $5.4M Larger Scale GCL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+53.8% +19.1% Higher Growth GCL
Operating Margin (TTM)
Profitability
-5.5% -41.7% Higher Margin GCL
Net Profit Margin
Profitability
-10.5% -41.9% Higher Margin GCL
Return on Equity (ROE)
Capital Efficiency
-67.3% -19.2% Higher ROE WOK
52-Week Range Position
Momentum
57% ($0–$2) 16% ($0–$7) Stronger Trend GCL
Beta / 30D Volatility
Risk Regime
1.52β · 75% Vol 38.49β · 153% Vol Lower Realized Risk GCL
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 25.6 / 100 (SELL) Higher Composite GCL
Trailing 12M Revenue (USD)
Operating Scale
$239M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
10.3% 17.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($0.29 Book/Sh · -67.3% ROE) -$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GCL +20.32 pp
GCL: +33.16% · WOK: +12.84%
3M Horizon GCL +145.51 pp
GCL: +101.42% · WOK: -44.09%
6M Horizon WOK +59.98 pp
GCL: +163.7% · WOK: +223.68%
1Y Horizon GCL +43.65 pp
GCL: -28.4% · WOK: -72.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GCL vs WOK. Trailing 12-month operating profitability (GCL -5.5% vs WOK -41.7%) and valuation multiples (GCL N/M vs WOK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$239M
Gross Margin10.3%
Op. Margin-5.5%
ROE / Fwd P/E-67.3% · N/M
WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GCL Moat Profile Cyclical / Execution-Driven Positioning
Electronic Gaming & Multimedia Operator
Competes within the Electronic Gaming & Multimedia value chain with $153.0M market capitalization and -5.5% operating margin.
OpEx & R&D Reinvestment 15.8% of Rev ($38M)
90D Engineering Disclosures 0 Published
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published

Investor FAQ GCL vs WOK Key Questions & Quantitative Answers

As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin). Defensive Composite Rating Caution: Although GCL compares more favorably head-to-head, both GCL (31.6/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

GCL leads the Growth & Scale pillar: GCL posts +53.8% YoY revenue growth and N/A YoY earnings growth on $239M TTM revenue (10.3% gross margin, -5.5% operating margin), compared with WOK at +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin). On trailing 12-month operating scale, GCL generates $239M in USD-normalized revenue versus $11M for WOK. In operating R&D and SG&A reinvestment, GCL deploys 15.8% of Rev ($38M) (0 90-day corporate R&D disclosures) versus 58.7% of Rev ($6.3M) (0 disclosures) for WOK.

GCL and WOK trade at balanced relative valuation multiples. GCL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-4.9% EBITDA margin), whereas WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GCL (-67.3% ROE) versus WOK (-19.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 75% Vol realized risk). By comparison, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

WORK Medical Technology Group LTD Class A Ordinary Shares (WOK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.